ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
125.01
+5.37 (4.49%)
At close: Jan 14, 2026, 4:00 PM EST
124.90
-0.11 (-0.09%)
After-hours: Jan 14, 2026, 6:20 PM EST
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 639.00K EUR in the quarter ending September 30, 2025, a decrease of -88.61%. This brings the company's revenue in the last twelve months to 5.31M, down -42.89% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
5.31M EUR
Revenue Growth
-42.89%
P/S Ratio
1,571.99
Revenue / Employee
76,971 EUR
Employees
69
Market Cap
9.80B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | 14.00K | 21.00K | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABVX News
- 2 days ago - Abivax: Don't Just Buy The Rumor, Buy The Fundamentals - Seeking Alpha
- 2 days ago - France has had no request for investment approval in biotech Abivax - official - Reuters
- 2 days ago - Abivax stock rockets 30% on Eli Lilly takeover speculation - Invezz
- 2 days ago - Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid - WSJ
- 2 days ago - Abivax shares soar 23% as media report reignites M&A chatter - Reuters
- 5 days ago - A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year - CNBC
- 7 days ago - Abivax Provides 2026 Corporate Outlook - GlobeNewsWire
- 22 days ago - Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy - Seeking Alpha